Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

591
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
591
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

693
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
693
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

631
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
631
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

720
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
720
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

616
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
616

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An Economical Innovative Use of a Dental Burr to Sharpen and Reuse Follicular Unit Extraction (FUE) Punches for Hair Transplantation.

Journal of cutaneous and aesthetic surgery·2022
Same author

Herpes zoster following vaccination with ChAdOx1 nCoV-19 Coronavirus vaccine (recombinant).

Indian journal of public health·2022
Same author

Unmasking Facial Tinea in the COVID-19 Era.

Indian journal of dermatology·2021
Same author

Use of silicone gel sheet to reduce pain during laser hair reduction of the upper lip.

Journal of the American Academy of Dermatology·2021
Same author

Evaluation of vascular endothelial growth factor - A release from platelet-rich fibrin, platelet-rich fibrin matrix, and dental pulp at different time intervals.

Journal of conservative dentistry : JCD·2021
Same author

Evaluation of Histological and pH Changes in Platelet-Rich Fibrin and Platelet-Rich Fibrin Matrix: A <i>In vitro</i> Study.

Contemporary clinical dentistry·2020

Related Experiment Video

Updated: Mar 19, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.6K

Pulse Therapy in Pemphigus: Ready Reckoner.

Anil Abraham1, Gillian Roga1, Anupa Mary Job1

  • 1Department of Dermatology, St. John's Medical College and Hospital, Bengaluru, Karnataka, India.

Indian Journal of Dermatology
|June 14, 2016
PubMed
Summary
This summary is machine-generated.

Pulse therapy, a common treatment for pemphigus, involves high-dose intravenous steroids and immunosuppressants. This article clarifies its administration, efficacy, and addresses ongoing debates for dermatology residents.

Keywords:
Modifications of pulse therapy in pemphiguspemphiguspulse therapy

More Related Videos

Technique of Conjunctival Biopsy and Direct Immunofluorescence for Diagnosing Mucous Membrane Pemphigoid
05:05

Technique of Conjunctival Biopsy and Direct Immunofluorescence for Diagnosing Mucous Membrane Pemphigoid

Published on: June 17, 2025

1.4K
Granulocyte-dependent Autoantibody-induced Skin Blistering
12:23

Granulocyte-dependent Autoantibody-induced Skin Blistering

Published on: October 12, 2012

11.0K

Related Experiment Videos

Last Updated: Mar 19, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.6K
Technique of Conjunctival Biopsy and Direct Immunofluorescence for Diagnosing Mucous Membrane Pemphigoid
05:05

Technique of Conjunctival Biopsy and Direct Immunofluorescence for Diagnosing Mucous Membrane Pemphigoid

Published on: June 17, 2025

1.4K
Granulocyte-dependent Autoantibody-induced Skin Blistering
12:23

Granulocyte-dependent Autoantibody-induced Skin Blistering

Published on: October 12, 2012

11.0K

Area of Science:

  • Dermatology
  • Immunology
  • Pharmacology

Background:

  • Pulse therapy is a widely used treatment for pemphigus.
  • Concerns persist regarding the rationale for high-dose intravenous steroids and immunosuppressants in pulse therapy.

Purpose of the Study:

  • To clarify the administration of pulse therapy for pemphigus.
  • To address controversies and modifications in pulse therapy for pemphigus.
  • To provide guidance for dermatology residents on pulse therapy protocols.

Main Methods:

  • Review of existing literature on pemphigus pulse therapy.
  • Analysis of reported controversies and modifications in treatment protocols.
  • Synthesis of evidence regarding efficacy and methodology.

Main Results:

  • Established efficacy and methodology of pulse therapy for pemphigus.
  • Identified key areas of debate concerning steroid and immunosuppressant use.
  • Highlighted recent modifications and alternative approaches in pulse therapy.

Conclusions:

  • Pulse therapy remains a valuable treatment for pemphigus, despite ongoing discussions.
  • Understanding the rationale and modifications is crucial for optimal patient outcomes.
  • Further research may refine current pulse therapy guidelines for pemphigus management.